H. Rizvi

D. Pe’er, M. Ladanyi, C. Rudin, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer.

Amanda R. Kulick, C. Rudin, J. Wolchok, 2022, Immunity.

Leveraging CD39 To Identify Tumor-Reactive CD8 T cells In Human Lung Cancer

Maria R. Ward, Amanda R. Kulick, C. Rudin, 2022 .

Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung Cancer

N. Hacohen, S. Digumarthy, C. Stewart, 2022, bioRxiv.

Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer

Martin L. Miller, Darwin Q. Ye, P. Beltrão, 2021, bioRxiv.

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

L. Zitvogel, M. Hellmann, J. Chaft, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers

J. Wolchok, M. Hellmann, J. Egger, 2020, Cancer discovery.

Diminished Ef ﬁ cacy of Programmed Death-(Ligand)1 Inhibition in STK11 - and KEAP1 -Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

S. Digumarthy, M. Tolstorukov, A. Cherniack, 2022 .

Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer

C. Rudin, J. Wolchok, M. Hellmann, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC

Ash A. Alizadeh, Daniel K. Wells, C. Liu, 2020, Clinical Cancer Research.

Diminished efficacy of PD-(L)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is impacted by KRAS mutation status.

S. Digumarthy, M. Tolstorukov, A. Cherniack, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer.

M. Ginsberg, M. Hellmann, M. Capanu, 2021, Lung cancer.

Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.

Julie L. Yang, M. Ladanyi, M. Berger, 2020, JAMA oncology.

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection.

P. Ascierto, J. McQuade, Douglas B. Johnson, 2018, European journal of cancer.

Beyond steroids: immunosuppressants in steroid-refractory/resistant immune related adverse events.

M. Kris, M. Lacouture, M. Hellmann, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study

M. Ladanyi, M. Zauderer, M. Kris, 2021, The Lancet. Digital health.

Lack of anti-tumor activity with the β-catenin expression inhibitor EZN-3892 in the C57BL/6J Min/+ model of intestinal carcinogenesis.

M. Bertagnolli, A. Briggs, H. Rizvi, 2014, Biochemical and biophysical research communications.

Systemic and oligo-acquired resistance to PD-(L)1 blockade in lung cancer.

C. Rudin, V. Rusch, R. Perez-Johnston, 2022, Clinical Cancer Research.

COVID-19 in patients with lung cancer

A. Drilon, M. Zauderer, C. Rudin, 2020, Annals of Oncology.

A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry

V. Torri, N. Reinmuth, H. Wakelee, 2022, Journal of Thoracic Oncology.

Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC.

Gregory Riely, D. Planchard, M. Hellmann, 2018 .

COVID-19 Presenting as Severe Rhabdomyolysis With Normal Renal Function

H. Rizvi, K. Frey, A. Shanbhag, 2020, Cureus.

Quantitative In Vivo Analyses Reveal a Complex Pharmacogenomic Landscape in Lung Adenocarcinoma

Christopher D. McFarland, D. Petrov, C. Rudin, 2020, Cancer Research.

A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma.

David R. Jones, N. Schultz, M. Ladanyi, 2020, JAMA surgery.

Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies.

N. Schultz, J. Warner, R. Shen, 2021, JAMA oncology.

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

N. Hacohen, S. Digumarthy, C. Stewart, 2023, Nature Genetics.

Efficacy of PD-(L)1 Blockade Monotherapy Compared to PD-(L)1 Blockade Plus Chemotherapy in First-Line PD-L1-Positive Advanced Lung Adenocarcinomas

M. Ladanyi, C. Rudin, M. Kris, 2022, medRxiv.

Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer.

P. Jänne, M. Tolstorukov, Rileen Sinha, 2021 .

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.

S. Digumarthy, M. Hellmann, K. Kehl, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort.

N. Schultz, M. Ladanyi, M. Berger, 2022, Cancer discovery.

P14.26 Diminished Efficacy of PD-(L)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma is Impacted by KRAS Mutation Status

S. Digumarthy, M. Tolstorukov, A. Cherniack, 2021 .

MA19.09 Concurrent Mutations in STK11 and KEAP1 is Associated with Resistance to PD-(L)1 Blockade in Patients with NSCLC Despite High TMB

C. Rudin, R. Shen, Gregory Riely, 2018, Journal of Thoracic Oncology.

PD-L1 expression, tumor mutation burden and response to immune checkpoint blockade in patients with HER2-mutant lung cancers.

A. Drilon, M. Kris, M. Arcila, 2018 .

Response and durability of anti-PD-(L)1 therapy in never- or light-smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression.

M. Mino‐Kenudson, A. Shaw, M. Hellmann, 2018 .

Abstract 2514: Inter-test variability in tumor mutational burden (TMB) quantification and identification of TMB thresholds

M. Hellmann, L. Sholl, E. Allen, 2019, Molecular and Cellular Biology / Genetics.

MA 05.02 STK11/LKB1 Loss of Function Genomic Alterations Predict Primary Resistance to PD-1/PD-L1 Axis Blockade in KRAS-Mutant NSCLC

C. Rudin, P. Jänne, I. Wistuba, 2017 .

STK11/LKB1 co-mutations to predict for de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma.

C. Rudin, P. Jänne, I. Wistuba, 2017 .

Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers.

D. Pe’er, M. Ladanyi, M. Kris, 2019, Journal of Clinical Oncology.

Immunohistochemical and molecular analysis of tyrosine kinase activity in desmoid tumors.

M. Bertagnolli, M. Redston, H. Rizvi, 2012, The Journal of surgical research.

Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis

Allison P. Heath, Marilyn M. Li, Jena V. Lilly, 2022, Scientific Reports.

Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer.

B. Taylor, M. Ladanyi, M. Berger, 2022, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Acquired resistance to PD-1 blockade in NSCLC.

Martin L. Miller, M. Hellmann, D. Memon, 2020 .

Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade.

Daniel K. Wells, Ansuman T. Satpathy, C. Rudin, 2023, Cancer cell.

Lesion Response and Intracranial Control of Brain Metastases From Non–small Cell Lung Cancer After Stereotactic Radiosurgery or Hypofractionated Radiation Therapy Combined With Checkpoint Inhibitors

M. Kris, Y. Yamada, K. Beal, 2017 .

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study

M. Ladanyi, C. Rudin, M. Kris, 2023, Journal for ImmunoTherapy of Cancer.

A Scalable Quality Assurance Process for Curating Oncology Electronic Health Records: The Project GENIE Biopharma Collaborative Approach

J. Warner, Gregory Riely, B. Park, 2022, JCO clinical cancer informatics.

Clinical and genomic predictors of brain metastases (BM) in non-small cell lung cancer (NSCLC): An AACR Project GENIE analysis.

Neha M Jain, N. Schultz, J. Warner, 2021 .